Poly Medicure appoints Indranil Mukherjee as Chief Executive Officer, Asia Pacific and India

Poly Medicure, India's leading medical device company with a dominant position in the medical consumables market, has announced the appointment of Indranil Mukherjee as Chief Executive Officer, Asia Pacific and India, effective 1 June 2026.

The appointment comes at a pivotal stage in Poly Medicure's growth journey as the company continues to strengthen its position as a leading global medical device manufacturer. With a growing international footprint, strategic acquisitions, expanding manufacturing capabilities, and a strong focus on innovation-led growth, Poly Medicure is broadening its presence across key markets and advancing its portfolio of high-value medical devices and healthcare solutions.

Based in India, Mukherjee will lead Poly Medicure's operations across India and the Asia Pacific region, with responsibility for driving commercial growth, deepening market penetration, strengthening strategic partnerships, and supporting the company's long-term expansion objectives.

Mukherjee is a seasoned medical technology executive with over 30 years of broad-based leadership experience spanning critical care, infusion therapy, renal care, surgical instruments, vascular systems, wound care, and implantable devices.

He has demonstrated track record of acting as a change agent, scaling up business and leading market expansion, M&A and integration, organisational restructuring, and strategy execution. He combines deep industry insight with data-driven decision-making to deliver sustainable business outcomes.

He built the foundational years of his career at B. Braun, where he managed the company's portfolios across India, before being transferred to B. Braun's headquarters in Germany as Global Sales Manager in 2010 and subsequently serving as Regional Head for Hospital Care at the Asia Pacific headquarters in Penang, Malaysia. In his role as Managing Director at B. Braun Group in India, he delivered a turnaround and sustained profitable growth across multiple product lines spanning three manufacturing plants and a team of over 2,000 colleagues. He later served as Group Chief Executive Officer of Translumina Therapeutics, a global cardiovascular implants company with operations in India and Germany.